Navigation Links
Valeant Pharmaceuticals to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
Date:5/1/2009

ALISO VIEJO, Calif., May 1 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today announced members of its senior management team will make a presentation at the Bank of America and Merrill Lynch 2009 Health Care Conference on Thursday, May 14, 2009 at 10:00 a.m. EDT. The conference will be held at The Palace Hotel in New York, NY.

A live webcast and audio archive of the presentation will be available on the company's Web site at www.valeant.com. Click on Investor Relations, and then the link to Events and Presentations. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. The webcast also can be accessed through the following URL: http://www.veracast.com/webcasts/bas/healthcare09/id84304207.cfm

About Valeant

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at www.valeant.com.

    Contact:
    Laurie Little
    Valeant Pharmaceuticals
    949-461-6002

(Logo: http://www.newscom.com/cgi-bin/prnh/2008112
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
4. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
5. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
6. Valeant Pharmaceuticals Appoints President of Valeant Pharmaceuticals International
7. Valeant Pharmaceuticals to Announce 2009 First Quarter Results on May 5, 2009
8. Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... (PRWEB) , ... September 01, ... ... seeking better therapeutic options to efficiently cure and prevent different malignancies. Some ... cancers have different pathophysiological properties due to which distinctive approach is necessary ...
(Date:9/1/2015)... ... September 01, 2015 , ... Splashtop Inc. , ... Remote Support , a solution optimized for MSPs and IT professionals looking for ... prices and inadequate customer services of existing remote support solution, many MSPs and ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza ... the MonaLisa Touch® , an innovative vaginal health laser procedure that prevents ... new hormone-free treatment for atrophic vaginitis, a condition that causes vaginal dryness, pelvic ...
(Date:9/1/2015)... PA (PRWEB) , ... September 01, 2015 , ... The ... 18 at The ACE Club and Green Valley Country Club in Lafayette Hill, PA. ... has raised more than $13.5 million for programs and services designed to support patients ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... government entities, announced today that it has hired Scott Sanderson, an experienced business ... this capacity, Sanderson will be responsible for establishing and managing new client relationships ...
Breaking Medicine News(10 mins):Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2
... the chances of having a heavy baby, study finds , , FRIDAY, ... during pregnancy, the more likely she is to have a large ... study finds. , Women who gained more than 40 pounds ... risk of having a baby weighing more than 9 pounds, the ...
... amino acid glycine has been shown to be anti-inflammatory ... dietary glycine protected both the lung and liver against ... and improved graft survival after liver transplantation. The influence ... was not known. , A research article to be ...
... accepted as a choice of treatment for advanced HCC. ... assessing perfusion changes due to TACE therapy for locally ... application of this technique in evaluating the efficacy of ... A research article published on October 7, 2008 in ...
... online at http://www.diabetesatlanta.org , ATLANTA, Oct. 31 ... could be present in more than,300,000 more, and kills five ... The answer is diabetes., And, new CDC data shows ... doubled in the past 10 years - with the worst ...
... consent for organ donation - where people have to opt out ... way to tackle a growing waiting list for transplant. , That ... donation and the illegal trade of body parts, who has recently ... There are more than 7,500 patients in the UK currently on ...
... 31 InStil Health,Insurance Co., a leading provider ... policies in South Carolina and Georgia, announced today,that ... president and,chief operating officer of the company., ... the health insurance industry,and extensive knowledge of the ...
Cached Medicine News:Health News:Excess Weight Gain During Pregnancy a Risk to Mother and Child 2Health News:As Diabetes Reaches Epidemic Levels in Georgia and U.S., Thousands Drawn to Diabetes University in Atlanta Nov. 8 2Health News:'Opt out' system could solve donor organ shortage, says researcher 2Health News:Jim Hart Named President, COO of InStil Health Insurance Co. 2
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
Reptilase-Time from Bothrops atrox...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Pefakit TAFI Calibrators and Controls...
Plasma Control Level 2 - 1 ml...
Medicine Products: